Sunday, 7 December 2014
Exhibition Hall-Poster Area (Sul America)
Arzu Didem Yalcin, MD
,
Genomics Research Center, Internal Medicine, Allergy and Clinical Immunology, Genomics Research Center, Academia Sinica,11529, Taipei, Taiwan., Taipei, Taiwan
Betul Celik
,
Department of Laboratory Medicine and Pathology, Mayo Clinic in Jacksonville,, Jacksonville, MA
Sukran Kose, As. Prof.
,
Department of Infectious Diseases and Clinical Microbiology, Allergy and Clinical Immunology Unit, Tepecik Education and Research Hospital. Izmir, Turkey., Turkey
Ayhan Cekin
,
Department of Gastroenterology, Antalya Training Hospital, Antalya, Turkey., Turkey
Derya Seyman
,
Department of Infectious Diseases and Clinical Microbiology, Antalya Education and Research Hospital. Turkey., Turkey
Saadet Gumuslu
,
Department of Medical Biochemistry, Faculty of Medicine, Akdeniz University, 07070, Antalya, Turkey., Turkey
Ata Nevzat Yalcin
,
Department of Infectious Diseases and Clinical Microbiology, Akdeniz University, 07070, Antalya, Turkey., Turkey
Ata Nevzat Yalcin
,
Department of Infectious Diseases and Clinical Microbiology, Akdeniz University, 07070, Antalya, Turkey., Turkey
Background: Chronic hepatitis C (HCV) infects approximately 170 million people and causes more than 350 000 deaths every year. Information regarding pathogenetic mechanism of acute hepatitis C infection is limited. Following innate immune activation, cellular immunity, including natural killer (NK) cell activation and antigen-specific CD8 cell proliferation occurs. CD8+ T lymphocytes directly kill infected cells via direct cell-cell contact, and release antiviral cytokines (e.g. IFN, TNF)
Methods:
Eleven HCV-treatment naive HCV infected patients were treated with weight-based ribavirin daily in addition to either weekly pegIFN alfa-2b at 1.5 ug/kg, weekly pegIFN alfa-2a, or albinterferon alfa-2b at 900mcg every 2 weeks. All patients gave written informed consent approved by the Institutional Review Board prior to enrollment in the studies. Intensive serum monitoring was completed at study visits day 0 (pretreatment), weeks 4, 6 and 12.
Results:
In this present study, we aimed to investigate the relationship between IFN treatment response, HCV viral load and sApo 2L levels. Eleven HCV-treatment naive HCV infected patients were treated with pegIFN alfa-2a. Intensive serum circulating Apo 2L levels were monitered at study visits day 0 (pretreatment), weeks 4, 6 and 12.HCV-RNA and sApo 2L levels decreased gradually with PegIF-α 2 treatment and the differences were significant between day 0 and 4th week (p=0.001, p<0.005 and p=0.01, p<0.005 respectively); between day 0 and 12th week (p=0.001, p<0.005 and p=0.001, p<0.000 respectively); between 6th week and 12th week (p=0.01, p<0.05 and p=0.01, p<0.05 respectively).
Conclusions: We suggest that, decreased level of circulating Apo 2L may reflect its increased binding to its ligand expressed on hepatocyte or lymphocyte under the influence of PegIFN treatment.
